The Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation is seeking to develop a comprehensive valuation model for biosimilar and interchangeable biological product market entry, with a forecast posted on 2025-12-10. The primary objective of this project is to create a detailed analytical framework that assesses the economic considerations and strategic decision-making process for bringing biosimilar products to market. While specific solicitation release dates are not explicitly stated, the project appears to be aligned with the existing contract's ultimate completion date of March 15, 2025.

The forecasted contract is associated with an Indefinite Delivery Contract (IDV) with a substantial ceiling value of $500,000,000.00, indicating significant potential for multiple task orders. The contract is a multiple-award instrument, suggesting that several vendors may be selected to perform work. Key points of contact for this opportunity include Sonal Parasrampuria (sonal.parasrampuria@hhs.gov) and Lydina Battle (lydina.battle@hhs.gov), both from HHS, who can provide additional details about the procurement. The contract falls under NAICS code 921190 for Other General Government Support, which provides context for the type of work being sought.

The existing contract being recompeted is Indefinite Delivery Contract HHSP233201500055I, originally awarded on March 16, 2015, with an ultimate completion date of March 15, 2025. This contract was issued by the HHS Program Support Center and was structured as a multiple-award task order contract with no specific set-aside provisions. The original contract's $500,000,000.00 ceiling value suggests it supported substantial government-wide research and analytical services, with this recompete continuing the mission of providing complex governmental support and research capabilities.

Cost of Biosimilar Product Development

Forecast facts

About this forecast

Forecast text

Work this forecast